STOCK TITAN

[Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Lexeo Therapeutics (LXEO): insider transaction disclosed. The company’s Chief Technical Officer filed a Form 4 showing 5,940 shares of common stock acquired on 10/15/2025 at a price of $0. Following this, sales on 10/17/2025 totaled 2,091 shares at a weighted average price of $8.935 and 24 shares at a weighted average price of $9.561, with both ranges detailed in the notes. The filing states the sales represent shares sold to cover tax obligations on the release of RSUs.

After these transactions, the reporting person beneficially owned 64,197 shares directly, which includes 49,687 RSUs, each representing a contingent right to one share of common stock.

Lexeo Therapeutics (LXEO): operazione di insider registrata. Il Chief Technical Officer dell'azienda ha presentato un Modulo 4 che mostra l'acquisto di 5.940 azioni ordinarie al prezzo di 0 dollari avvenuto il 15/10/2025. A seguito di ciò, le vendite del 17/10/2025 ammontano a 2.091 azioni a un prezzo medio ponderato di 8,935 dollari e 24 azioni a un prezzo medio ponderato di 9,561 dollari, con entrambe le fasce dettagliate nelle note. La dichiarazione afferma che le vendite rappresentano azioni vendute per coprire obblighi fiscali sul rilascio degli RSU. Dopo queste operazioni, la persona segnalata deteneva direttamente 64.197 azioni, tra cui 49.687 RSU, ognuna delle quali rappresenta un diritto contingente a una azione ordinaria.
Lexeo Therapeutics (LXEO): operación de insider divulgada. El Director Técnico de la empresa presentó un Formulario 4 que muestra la compra de 5.940 acciones comunes a un precio de 0 USD, realizada el 15/10/2025. A continuación, las ventas del 17/10/2025 sumaron 2.091 acciones a un precio medio ponderado de 8,935 USD y 24 acciones a un precio medio ponderado de 9,561 USD, con ambos rangos detallados en las notas. El informe indica que las ventas representan acciones vendidas para cubrir obligaciones fiscales por la liberación de RSU. Después de estas transacciones, la persona reportante poseía directamente 64.197 acciones, incluidas 49.687 RSU, cada una representando un derecho contingente a una acción común.

Lexeo Therapeutics (LXEO): 내부자 거래 공개. 회사의 최고 기술 책임자(CTO)가 Form 4를 제출하여 2025년 10월 15일에 5,940주의 보통주를 0달러에 취득했음을 보여줍니다. 그 후 2025년 10월 17일의 매도는 가중 평균가 8.935달러로 2,091주, 그리고 가중 평균가 9.561달러로 24주를 매도한 것으로, 두 범위가 노트에 상세히 기재되어 있습니다. 제출서에는 이 매도가 RSU 해제에 따른 세금 의무를 충당하기 위한 주식 매도임을 명시합니다. 이러한 거래 후, 보고인은 직접 64,197주의 주식을 보유하게 되었으며, 그중 49,687 RSU가 포함되어 있으며, 각 RSU는 보통주 1주에 대한 잠정적 권리를 나타냅니다.

Lexeo Therapeutics (LXEO) : transaction d'initié divulguée. Le directeur technique de l'entreprise a déposé le formulaire 4 montrant l'acquisition de 5 940 actions ordinaires au prix de 0 $ le 15/10/2025. Suite à cela, les ventes du 17/10/2025 totalisent 2 091 actions à un cours moyen pondéré de 8,935 $ et 24 actions à un cours moyen pondéré de 9,561 $, les deux fourchettes étant détaillées dans les notes. Le dossier indique que les ventes représentent des actions vendues pour couvrir les obligations fiscales liées à la levée des RSU. Après ces transactions, la personne faisant l'objet du rapport détenait directement 64 197 actions, dont 49 687 RSU, chacune représentant un droit éventuel sur une action ordinaire.
Lexeo Therapeutics (LXEO): Insider-Transaktion gemeldet. Der Chief Technical Officer des Unternehmens reichte ein Formular 4 ein, das den Erwerb von 5.940 Stammaktien zum Preis von 0 USD am 15.10.2025 zeigt. Im Anschluss beliefen sich die Verkäufe am 17.10.2025 auf 2.091 Aktien zu einem gewichteten Durchschnittspreis von 8,935 USD und 24 Aktien zu einem gewichteten Durchschnittspreis von 9,561 USD, wobei beide Bereiche in den Notizen erläutert werden. Aus dem Filing geht hervor, dass die Verkäufe Aktienverkauf zur Deckung von Steuerverpflichtungen bei der Freigabe von RSUs darstellen. Nach diesen Transaktionen hielt die meldende Person direkt 64.197 Aktien, davon 49.687 RSUs, von denen jede ein bedingtes Recht auf eine Stammaktie darstellt.
Lexeo Therapeutics (LXEO): تم الكشف عن صفقة داخلية. قدّم المدير الفني التنفيذي للشركة نموذج 4 الذي يُظهر شراء 5,940 سهماً من الأسهم العادية بسعر 0 دولار في 15/10/2025. تبع ذلك بيع في 17/10/2025 مقدارها 2,091 سهماً بسعر متوسّط مُوزَّن 8.935 دولار و24 سهماً بسعر متوسّط مُوزَّن 9.561 دولار، مع تفصيل كلا النطاقين في الملاحظات. تنص الوثيقة على أن البيع يمثل أسهماً مباعة لتغطية الالتزامات الضريبية المرتبطة بإطلاق RSUs. بعد هذه المعاملات، أصبح الشخص المبلّغ عنه يملك مباشرة 64,197 سهماً، بما في ذلك 49,687 RSU، وكل RSU يمثل حقاً مشروطاً في سهم عادي واحد.
Lexeo Therapeutics (LXEO): 内幕交易披露。公司首席技术官提交的表格4显示于2025-10-15以0美元价格购买了5,940股普通股。随后,2025-10-17的抛售合计2,091股,加权平均价格为8.935美元,以及24股,加权平均价格为9.561美元,两项范围在注释中有详细说明。文件称这些出售是为覆盖RSU解禁产生的税务义务而出售。经此等交易后,报告人直接持有64,197股,其中包括49,687股RSU,每股RSU代表对普通股的一项或有权利。
Positive
  • None.
Negative
  • None.
Lexeo Therapeutics (LXEO): operazione di insider registrata. Il Chief Technical Officer dell'azienda ha presentato un Modulo 4 che mostra l'acquisto di 5.940 azioni ordinarie al prezzo di 0 dollari avvenuto il 15/10/2025. A seguito di ciò, le vendite del 17/10/2025 ammontano a 2.091 azioni a un prezzo medio ponderato di 8,935 dollari e 24 azioni a un prezzo medio ponderato di 9,561 dollari, con entrambe le fasce dettagliate nelle note. La dichiarazione afferma che le vendite rappresentano azioni vendute per coprire obblighi fiscali sul rilascio degli RSU. Dopo queste operazioni, la persona segnalata deteneva direttamente 64.197 azioni, tra cui 49.687 RSU, ognuna delle quali rappresenta un diritto contingente a una azione ordinaria.
Lexeo Therapeutics (LXEO): operación de insider divulgada. El Director Técnico de la empresa presentó un Formulario 4 que muestra la compra de 5.940 acciones comunes a un precio de 0 USD, realizada el 15/10/2025. A continuación, las ventas del 17/10/2025 sumaron 2.091 acciones a un precio medio ponderado de 8,935 USD y 24 acciones a un precio medio ponderado de 9,561 USD, con ambos rangos detallados en las notas. El informe indica que las ventas representan acciones vendidas para cubrir obligaciones fiscales por la liberación de RSU. Después de estas transacciones, la persona reportante poseía directamente 64.197 acciones, incluidas 49.687 RSU, cada una representando un derecho contingente a una acción común.

Lexeo Therapeutics (LXEO): 내부자 거래 공개. 회사의 최고 기술 책임자(CTO)가 Form 4를 제출하여 2025년 10월 15일에 5,940주의 보통주를 0달러에 취득했음을 보여줍니다. 그 후 2025년 10월 17일의 매도는 가중 평균가 8.935달러로 2,091주, 그리고 가중 평균가 9.561달러로 24주를 매도한 것으로, 두 범위가 노트에 상세히 기재되어 있습니다. 제출서에는 이 매도가 RSU 해제에 따른 세금 의무를 충당하기 위한 주식 매도임을 명시합니다. 이러한 거래 후, 보고인은 직접 64,197주의 주식을 보유하게 되었으며, 그중 49,687 RSU가 포함되어 있으며, 각 RSU는 보통주 1주에 대한 잠정적 권리를 나타냅니다.

Lexeo Therapeutics (LXEO) : transaction d'initié divulguée. Le directeur technique de l'entreprise a déposé le formulaire 4 montrant l'acquisition de 5 940 actions ordinaires au prix de 0 $ le 15/10/2025. Suite à cela, les ventes du 17/10/2025 totalisent 2 091 actions à un cours moyen pondéré de 8,935 $ et 24 actions à un cours moyen pondéré de 9,561 $, les deux fourchettes étant détaillées dans les notes. Le dossier indique que les ventes représentent des actions vendues pour couvrir les obligations fiscales liées à la levée des RSU. Après ces transactions, la personne faisant l'objet du rapport détenait directement 64 197 actions, dont 49 687 RSU, chacune représentant un droit éventuel sur une action ordinaire.
Lexeo Therapeutics (LXEO): Insider-Transaktion gemeldet. Der Chief Technical Officer des Unternehmens reichte ein Formular 4 ein, das den Erwerb von 5.940 Stammaktien zum Preis von 0 USD am 15.10.2025 zeigt. Im Anschluss beliefen sich die Verkäufe am 17.10.2025 auf 2.091 Aktien zu einem gewichteten Durchschnittspreis von 8,935 USD und 24 Aktien zu einem gewichteten Durchschnittspreis von 9,561 USD, wobei beide Bereiche in den Notizen erläutert werden. Aus dem Filing geht hervor, dass die Verkäufe Aktienverkauf zur Deckung von Steuerverpflichtungen bei der Freigabe von RSUs darstellen. Nach diesen Transaktionen hielt die meldende Person direkt 64.197 Aktien, davon 49.687 RSUs, von denen jede ein bedingtes Recht auf eine Stammaktie darstellt.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Otero Jose Manuel

(Last) (First) (Middle)
C/O LEXEO THERAPEUTICS, INC.
345 PARK AVENUE SOUTH, FLOOR 6

(Street)
NEW YORK NY 10010

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Technical Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/15/2025 A 5,940 A $0 66,312 D
Common Stock 10/17/2025 S(1) 2,091 D $8.935(2) 64,221 D
Common Stock 10/17/2025 S(1) 24 D $9.561(3) 64,197(4) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents a sale to cover tax obligations on the release of Restricted Stock Units ("RSUs").
2. This transaction was executed in multiple trades at prices ranging from $8.53 to $9.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. This transaction was executed in multiple trades at prices ranging from $9.53 to $9.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
4. Includes 49,687 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
/s/ Youjin Choi, Attorney-in-Fact 10/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did LXEO disclose in this Form 4?

The CTO reported acquiring 5,940 shares at $0 on 10/15/2025 and selling 2,091 and 24 shares on 10/17/2025 at weighted average prices.

Why were LXEO shares sold by the reporting person?

The filing states the sales were to cover tax obligations on the release of Restricted Stock Units (RSUs).

What prices were the LXEO sales executed at?

Weighted averages of $8.935 (range $8.53–$9.52) for 2,091 shares and $9.561 (range $9.53–$9.59) for 24 shares.

How many LXEO shares does the insider now own?

Beneficial ownership after the transactions is 64,197 shares held directly, including 49,687 RSUs.

What role does the reporting person hold at LXEO?

The reporting person is the company’s Chief Technical Officer.

Are the RSUs in LXEO equivalent to common shares?

Each RSU represents a contingent right to receive one share of common stock.
Lexeo Therapeutics Inc

NASDAQ:LXEO

LXEO Rankings

LXEO Latest News

LXEO Latest SEC Filings

LXEO Stock Data

473.59M
49.10M
0.53%
89.37%
9.69%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK